MERZ PHARMACEUTICALS GMBH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1908-01-01

Employees: 101

Market Cap: -

Website: https://www.radiesse.de

Clinical Trials

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2

Phase 3

Completed

Conditions: Moderate to Severe Glabellar Frown Lines

Interventions: Drug: IncobotulinumtoxinA (Xeomin) (20 Units)
Drug: Placebo

First Posted Date: 2008-10-09

Last Posted Date: 2013-02-27

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 276

Registration Number: NCT00770029

Locations: 🇺🇸
Flynn Consulting PLLC, Raleigh, North Carolina, United States
🇺🇸
Skin Care Center, Los Angeles, California, United States
🇺🇸
Coleman William, Meatrie, Louisiana, United States

and more 5 locations

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

Phase 3

Completed

Conditions: Moderate to Severe Glabellar Frown Lines

Interventions: Drug: IncobotulinumtoxinA (Xeomin) (20 Units)
Drug: Placebo

First Posted Date: 2008-10-09

Last Posted Date: 2011-10-07

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 271

Registration Number: NCT00770211

Locations: 🇺🇸
About Skin Dermatoloy, Englewood, Colorado, United States
🇺🇸
Laser & Skin Surgery Center of Indiana, Carmel, Indiana, United States
🇺🇸
Frederic Brandt, Coral Gables, Florida, United States

and more 5 locations

Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus

Phase 3

Completed

Conditions: Subjective Tinnitus

Interventions: Drug: Neramexane mesylate
Drug: Placebo

First Posted Date: 2008-08-22

Last Posted Date: 2016-02-04

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 411

Registration Number: NCT00739635

Locations: 🇬🇧
The Horsley Medical Practice, East Horsley, Leatherhead, Surrey, United Kingdom
🇪🇸
Hospital Universitario Príncipe de Asturias, Madrid, Spain
🇩🇪
HNO-Praxis im Gesundheitszentrum Walsum, Duisburg, Germany

and more 48 locations

Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Neramexane mesylate

First Posted Date: 2008-07-09

Last Posted Date: 2009-12-07

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 64

Registration Number: NCT00712283

Locations: 🇩🇪
Merz Pharmaceuticals, Frankfurt/Main, Germany

Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines

Phase 3

Completed

Conditions: Healthy

First Posted Date: 2008-06-10

Last Posted Date: 2012-10-30

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 108

Registration Number: NCT00694148

Locations: 🇩🇪
Dr. Matthias Imhof, Medico Palais Bad Soden, Bad Soden, Hessen, Germany

Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus

Phase 2

Completed

Conditions: Nystagmus, Congenital Idiopathic
Nystagmus, Acquired

Interventions: Drug: Neramexane mesylate

First Posted Date: 2008-04-18

Last Posted Date: 2009-11-26

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 48

Registration Number: NCT00661440

Locations: 🇬🇧
University of Leicester, Leicester Royal Infirmary, Ophthalmology Group, Leicester, United Kingdom

Memantine and Antipsychotics Use

Phase 4

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Memantine

First Posted Date: 2008-04-01

Last Posted Date: 2011-09-26

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 19

Registration Number: NCT00649220

Locations: 🇩🇪
Alexianer Hospital, Krefeld, North-Rhine-Westphalia, Germany

Memantine - Communication Study

Phase 3

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Memantine-HCl

First Posted Date: 2008-02-26

Last Posted Date: 2011-11-01

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 107

Registration Number: NCT00624026

Locations: 🇩🇪
Central Medical Affairs, Frankfurt/Main, Germany

Efficacy and Safety of NT 201 in the Treatment of Lateral Periorbital Wrinkles

Phase 3

Completed

Conditions: Lateral Periorbital Wrinkles

Interventions: Drug: IncobotulinumtoxinA (Xeomin)
Drug: Placebo

First Posted Date: 2007-10-10

Last Posted Date: 2012-03-08

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 111

Registration Number: NCT00541723

Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia

Phase 4

Completed

Conditions: Cervical Dystonia

Interventions: Drug: NT 201

First Posted Date: 2007-10-10

Last Posted Date: 2013-06-04

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 82

Registration Number: NCT00541905

Locations: 🇩🇪
Medizinische Hochschule Hannover (LKP), Hannover, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy